icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Impact of Hepatitis C Treatment With Glecaprevir + Pibrentasvir on Patient's Health Related Quality of Life: Results From Phase 3 CERTAIN Trials
 
 
  Reported by Jules Levin
AASLD - American Association for The study of Liver Diseases (AASLD) ° October 20 - 24, 2017 ° Washington DC, USA
 
Hiromitsu Kumada,1 Kazuaki Chayama,2 Darshan Mehta,3,4 Brett Pinsky4 1Toranomon Hospital, Kanagawa, Japan; 2Hiroshima University, Hiroshima, Japan; 3Schaeffer Center for Health Policy and Economics, University of Southern California, Mettawa, IL, United States; 4Health Economics and Outcomes Research, AbbVie Inc., Mettawa, IL, United States

1027171

1027172

1027173

1027174

1027175

1027176

1027177

1027178

1027179